Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.

Jelle M BeerninkFrederik PerssonNiels JongsGozewijn D LavermanGlenn M ChertowJohn J V McMurrayAnna Maria LangkildeRicardo Correa-RotterPeter RossingC David SjöströmRobert D TotoDavid C WheelerHiddo J Lambers Heerspink

Published in: Diabetes care (2023)

Dapagliflozin reduced kidney and cardiovascular events in patients with type 2 diabetes and CKD across baseline GLT class or classes in combination.

Keyphrases

cardiovascular events
cardiovascular disease
chronic kidney disease
coronary artery disease
type diabetes
adipose tissue
skeletal muscle
weight loss